Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved bevacizumab in combination with erlotinib for reimbursement as a treatment option for the first-line treatment of adult patients with unresectable advanced, metastatic, or recurrent non-small cell lung cancer with EGFR activating variants.
This is written in the approval document as:
In combination with erlotinib is indicated for the first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous cell lung cancer with Epidermal Growth Factor (EGFR) activating mutations
Citation
Bevacizumab 15mg/kg Therapy - 21 days, 2021, version number 6, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/215.pdfTherapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | EGFR oncogenic variants | Non-Small Cell Lung Cancer | Bevacizumab, Erlotinib |